Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the audited Standalone and Consolidated Financial Results for the year ended ....
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.3 pts more than Nifty Microcap 250 and 14.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Solara Active Pharma Sciences reported consolidated revenue of Rs. 1,368.98 Crores for FY2025-26, up from Rs. 1,283.76 Crores in the previous year (6.6% revenue growth). However, the company posted a consolidated net loss of Rs. 7.41 Crores compared to a profit of Rs. 0.54 Crores in FY2024-25. The loss was primarily due to higher finance costs (Rs. 94.75 Crores) and an exceptional charge of Rs. 5.89 Crores related to gratuity and compensated absences under new labour codes. The company had accumulated losses of Rs. 319.33 Crores as of March 31, 2026. Q4 FY26 showed recovery with standalone profit of Rs. 9.73 Crores. The company is undertaking a rights issue and expects to receive Rs. 134.99 Crores from the second and final call to address liquidity concerns. Deloitte Haskins & Sells LLP issued an unmodified opinion on the audited results.
The company is facing financial stress with accumulated losses and negative working capital, but the Q4 turnaround and ongoing rights issue provide some relief. Shareholders should monitor the rights issue completion and revenue growth trajectory to assess long-term viability.